FindTrial
Sign In

Investigation of the clinical safety and efficacy of favipiravir (Avigan tablets) in patients with novel or re-emerging influenza virus infections

Investigation of the clinical safety and efficacy of favipiravir (Avigan tablets) in patients with novel or re-emerging influenza virus infections

Status
Unknown
Phases
Unknown
Study type
Observational
Source
JPRN
Registry ID
JPRN-jRCT1080223849
Enrollment
Unknown
Registered
2018-03-20
Start date
2018-03-20
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Novel or re-emerging influenza infections

Interventions

investigational material(s) Generic name etc : Favipiravir (Avigan tablets) 200 mg INN of investigational material : Favipiravir Therapeutic category code : 625 Anti-virus agents Dosage and Administra

Sponsors

FUJIFILM Toyama Chemical Co., Ltd. (Former Toyama Chemical Co., Ltd.)
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: novel or re-emerging influenza infections who take favipiravir (Avigan tablets) and any gender welcome.

Exclusion criteria

Exclusion criteria: Pregnant women or women suspected of being pregnant Patients with known hypersensitivity to favipiravir or any of its excipients

Design outcomes

Primary

MeasureTime frame
Efficacy Evaluation of therapy—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026